Steroid Injections for Sacroiliac Joint Dysfunction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two steroid injections to determine which better relieves pain in the sacroiliac (SI) joint, connecting the spine to the pelvis. The study compares dexamethasone and methylprednisolone injections to identify which provides more effective pain relief. Individuals with ongoing lower back or buttock pain for at least two weeks and diagnosed with SI joint pain might be suitable candidates. Participants should have experienced significant pain relief shortly after a previous SI joint injection. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, aiming to understand how it benefits more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have had certain steroid injections or treatments in the past year, you may not be eligible to participate.
What is the safety track record for these treatments?
Research shows that steroid injections for sacroiliac joint pain are generally safe. Studies have found no complications in patients receiving MRI-guided steroid injections. Specifically, dexamethasone is well-tolerated, with no major safety concerns reported.
Research also supports the safety of methylprednisolone. Commonly used for joint injections, it provides pain relief without significant side effects, though it can cause minor effects like temporary increases in blood sugar levels.
Both dexamethasone and methylprednisolone have been used safely for sacroiliac joint injections in most patients. This trial aims to compare these two to determine which one might be more effective at relieving pain.12345Why are researchers enthusiastic about this study treatment?
Unlike the standard treatments for sacroiliac joint dysfunction, which often involve oral pain medications or physical therapy, this trial is exploring the effectiveness of steroid injections with two different formulations. Researchers are excited because these injections use dexamethasone and methylprednisolone, which are potent anti-inflammatory steroids that can be directly administered to the affected joint. This direct delivery method allows for potentially faster and more targeted relief compared to systemic treatments. Additionally, the trial compares non-particulate dexamethasone against particulate methylprednisolone, which could reveal differences in how these steroids act in the body, offering insights into optimizing injection therapies for better outcomes.
What evidence suggests that this trial's treatments could be effective for SI joint pain?
This trial will compare the effectiveness of dexamethasone and methylprednisolone for treating sacroiliac (SI) joint dysfunction. Research has shown that both dexamethasone, administered to participants in one trial arm, and methylprednisolone, given to participants in another arm, can effectively treat SI joint pain. Specifically, one study found that dexamethasone significantly reduced pain, with 85% of patients experiencing relief within four weeks after injection. Methylprednisolone also provides strong pain relief when injected into the SI joint, especially with guided techniques. Both treatments have proven effective in managing SI joint problems and reducing pain. This evidence suggests that both steroids are viable options for treating pain related to SI joint issues.13678
Who Is on the Research Team?
Reza Ehsanian, MD, PhD
Principal Investigator
University of New Mexico Department of Anesthesiology and Critical Care
Are You a Good Fit for This Trial?
This trial is for adults over 18 with unilateral low back or buttocks pain lasting at least two weeks, and a pain score of at least 5/10. They must have been diagnosed with sacroiliac joint pain by a specialist and shown significant improvement after an initial injection. Participants need to understand English, consent to treatment, and be able to attend follow-ups.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an injection of either dexamethasone or methylprednisolone to the sacroiliac joints
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dexamethasone
- Methylprednisolone
Dexamethasone is already approved in European Union, United States, Canada, Japan for the following indications:
- Inflammation
- Allergic reactions
- Respiratory diseases
- Skin conditions
- Eye diseases
- Immune system disorders
- Inflammatory conditions
- Allergic states
- Respiratory diseases
- Blood disorders
- Neoplastic diseases
- Nervous system disorders
- Inflammation
- Allergic reactions
- Respiratory diseases
- Skin conditions
- Eye diseases
- Inflammatory conditions
- Allergic states
- Respiratory diseases
- Blood disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of New Mexico
Lead Sponsor